Apeloa Pharmaceutical Co Ltd (000739) - Net Assets

Latest as of March 2026: CN¥6.57 Billion CNY ≈ $961.28 Million USD

Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) has net assets worth CN¥6.57 Billion CNY (≈ $961.28 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.25 Billion ≈ $1.79 Billion USD) and total liabilities (CN¥5.68 Billion ≈ $831.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000739 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥6.57 Billion
% of Total Assets 53.63%
Annual Growth Rate 18.23%
5-Year Change 25.42%
10-Year Change 142.55%
Growth Volatility 60.25

Apeloa Pharmaceutical Co Ltd - Net Assets Trend (1994–2025)

This chart illustrates how Apeloa Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Apeloa Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Apeloa Pharmaceutical Co Ltd (1994–2025)

The table below shows the annual net assets of Apeloa Pharmaceutical Co Ltd from 1994 to 2025. For live valuation and market cap data, see 000739 market cap overview.

Year Net Assets Change
2025-12-31 CN¥6.35 Billion
≈ $928.67 Million		 -5.98%
2024-12-31 CN¥6.75 Billion
≈ $987.72 Million		 +8.34%
2023-12-31 CN¥6.23 Billion
≈ $911.71 Million		 +12.89%
2022-12-31 CN¥5.52 Billion
≈ $807.64 Million		 +9.08%
2021-12-31 CN¥5.06 Billion
≈ $740.44 Million		 +15.24%
2020-12-31 CN¥4.39 Billion
≈ $642.49 Million		 +16.53%
2019-12-31 CN¥3.77 Billion
≈ $551.37 Million		 +12.64%
2018-12-31 CN¥3.35 Billion
≈ $489.52 Million		 +9.68%
2017-12-31 CN¥3.05 Billion
≈ $446.31 Million		 +16.57%
2016-12-31 CN¥2.62 Billion
≈ $382.88 Million		 +8.26%
2015-12-31 CN¥2.42 Billion
≈ $353.65 Million		 +4.81%
2014-12-31 CN¥2.31 Billion
≈ $337.43 Million		 +24.12%
2013-12-31 CN¥1.86 Billion
≈ $271.86 Million		 +36.05%
2012-12-31 CN¥1.37 Billion
≈ $199.83 Million		 +10.89%
2011-12-31 CN¥1.23 Billion
≈ $180.21 Million		 +52.30%
2010-12-31 CN¥808.57 Million
≈ $118.32 Million		 +1.73%
2009-12-31 CN¥794.78 Million
≈ $116.30 Million		 +3.47%
2008-12-31 CN¥768.11 Million
≈ $112.40 Million		 +2.40%
2007-12-31 CN¥750.11 Million
≈ $109.76 Million		 +72.02%
2006-12-31 CN¥436.05 Million
≈ $63.81 Million		 +5.86%
2005-12-31 CN¥411.93 Million
≈ $60.28 Million		 +11.01%
2004-12-31 CN¥371.08 Million
≈ $54.30 Million		 +12.85%
2003-12-31 CN¥328.83 Million
≈ $48.12 Million		 +11.97%
2002-12-31 CN¥293.69 Million
≈ $42.98 Million		 +13.09%
2001-12-31 CN¥259.70 Million
≈ $38.00 Million		 -5.30%
2000-12-31 CN¥274.23 Million
≈ $40.13 Million		 -10.94%
1999-12-31 CN¥307.93 Million
≈ $45.06 Million		 +36.07%
1998-12-31 CN¥226.31 Million
≈ $33.12 Million		 +2.19%
1997-12-31 CN¥221.45 Million
≈ $32.41 Million		 +341.87%
1996-12-31 CN¥50.12 Million
≈ $7.33 Million		 +4.88%
1995-12-31 CN¥47.79 Million
≈ $6.99 Million		 +35.19%
1994-12-31 CN¥35.35 Million
≈ $5.17 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Apeloa Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 90866.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥5.11 Billion 80.68%
Common Stock CN¥1.16 Billion 18.28%
Other Components CN¥66.01 Million 1.04%
Total Equity CN¥6.34 Billion 100.00%

Apeloa Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Apeloa Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
ChengDu Hi-Tech Development Co Ltd
SHE:000628
 $2.76 Billion
Northeast Securities Co Ltd
SHE:000686
 $2.76 Billion
Eurazeo
PA:RF
 $2.76 Billion
Taseko Mines Ltd
TO:TKO
 $2.77 Billion
IHS Holding Ltd
NYSE:IHS
 $2.76 Billion
Soleno Therapeutics Inc
NASDAQ:SLNO
 $2.76 Billion
Treasury Wine Estates Ltd
AU:TWE
 $2.76 Billion
Steadfast Group Limited
F:1S6
 $2.76 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Apeloa Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 6,741,964,785 to 6,338,427,056, a change of -403,537,729 (-6.0%).
  • Net income of 890,677,997 contributed positively to equity growth.
  • Dividend payments of 812,455,782 reduced retained earnings.
  • Share repurchases of 482,060,089 reduced equity.
  • Other comprehensive income decreased equity by 347,358,422.
  • Other factors increased equity by 347,658,567.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥890.68 Million +14.05%
Dividends Paid CN¥812.46 Million -12.82%
Share Repurchases CN¥482.06 Million -7.61%
Other Comprehensive Income CN¥-347.36 Million -5.48%
Other Changes CN¥347.66 Million +5.48%
Total Change CN¥- -5.99%

Book Value vs Market Value Analysis

This analysis compares Apeloa Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.96x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 292.52x to 2.96x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.06 CN¥16.29 x
1995-12-31 CN¥0.08 CN¥16.29 x
1996-12-31 CN¥0.08 CN¥16.29 x
1997-12-31 CN¥0.35 CN¥16.29 x
1998-12-31 CN¥0.36 CN¥16.29 x
1999-12-31 CN¥0.48 CN¥16.29 x
2000-12-31 CN¥0.43 CN¥16.29 x
2001-12-31 CN¥0.39 CN¥16.29 x
2002-12-31 CN¥0.44 CN¥16.29 x
2003-12-31 CN¥0.48 CN¥16.29 x
2004-12-31 CN¥0.53 CN¥16.29 x
2005-12-31 CN¥0.59 CN¥16.29 x
2006-12-31 CN¥0.70 CN¥16.29 x
2007-12-31 CN¥1.12 CN¥16.29 x
2008-12-31 CN¥1.11 CN¥16.29 x
2009-12-31 CN¥1.16 CN¥16.29 x
2010-12-31 CN¥1.15 CN¥16.29 x
2011-12-31 CN¥1.25 CN¥16.29 x
2012-12-31 CN¥2.78 CN¥16.29 x
2013-12-31 CN¥2.25 CN¥16.29 x
2014-12-31 CN¥2.15 CN¥16.29 x
2015-12-31 CN¥2.09 CN¥16.29 x
2016-12-31 CN¥2.29 CN¥16.29 x
2017-12-31 CN¥2.65 CN¥16.29 x
2018-12-31 CN¥2.84 CN¥16.29 x
2019-12-31 CN¥3.20 CN¥16.29 x
2020-12-31 CN¥3.73 CN¥16.29 x
2021-12-31 CN¥4.29 CN¥16.29 x
2022-12-31 CN¥4.71 CN¥16.29 x
2023-12-31 CN¥5.32 CN¥16.29 x
2024-12-31 CN¥5.82 CN¥16.29 x
2025-12-31 CN¥5.50 CN¥16.29 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Apeloa Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 14.05%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.13%
  • • Asset Turnover: 0.79x
  • • Equity Multiplier: 1.94x
  • Recent ROE (14.05%) is above the historical average (11.14%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 29.88% 3.19% 2.34x 4.00x CN¥7.03 Million
1995 27.18% 3.77% 2.35x 3.06x CN¥8.21 Million
1996 28.38% 3.86% 2.24x 3.28x CN¥9.21 Million
1997 10.39% 6.26% 0.94x 1.77x CN¥856.56K
1998 1.79% 0.97% 0.92x 2.01x CN¥-18.50 Million
1999 2.49% 3.38% 0.43x 1.70x CN¥-23.00 Million
2000 -1.24% -1.90% 0.40x 1.66x CN¥-30.69 Million
2001 -10.47% -18.24% 0.24x 2.38x CN¥-50.58 Million
2002 11.34% 4.79% 0.96x 2.47x CN¥3.72 Million
2003 11.19% 4.44% 0.89x 2.82x CN¥3.64 Million
2004 10.67% 4.29% 0.75x 3.34x CN¥2.23 Million
2005 11.75% 4.23% 0.90x 3.08x CN¥6.52 Million
2006 13.43% 4.50% 0.94x 3.19x CN¥13.62 Million
2007 4.27% 2.92% 0.65x 2.26x CN¥-40.92 Million
2008 3.91% 2.37% 0.71x 2.34x CN¥-45.21 Million
2009 4.42% 2.49% 0.78x 2.27x CN¥-43.08 Million
2010 3.01% 1.56% 0.82x 2.33x CN¥-55.24 Million
2011 6.23% 2.69% 0.78x 2.99x CN¥-45.77 Million
2012 10.15% 3.94% 0.85x 3.04x CN¥2.02 Million
2013 9.34% 4.34% 0.83x 2.60x CN¥-11.88 Million
2014 13.97% 7.61% 0.84x 2.20x CN¥91.57 Million
2015 8.62% 4.80% 0.80x 2.23x CN¥-33.44 Million
2016 10.05% 5.51% 0.85x 2.15x CN¥1.25 Million
2017 8.41% 4.62% 0.98x 1.87x CN¥-48.41 Million
2018 11.08% 5.81% 1.11x 1.72x CN¥36.04 Million
2019 14.69% 7.67% 1.11x 1.73x CN¥176.60 Million
2020 18.60% 10.37% 1.05x 1.71x CN¥377.66 Million
2021 18.88% 10.69% 0.99x 1.79x CN¥449.55 Million
2022 17.95% 9.38% 0.88x 2.18x CN¥437.99 Million
2023 16.96% 9.20% 0.90x 2.05x CN¥433.07 Million
2024 15.29% 8.58% 0.94x 1.89x CN¥356.93 Million
2025 14.05% 9.13% 0.79x 1.94x CN¥256.84 Million

Industry Comparison

This section compares Apeloa Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,086,370,990
  • Average return on equity (ROE) among peers: 6.87%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Apeloa Pharmaceutical Co Ltd (000739) CN¥6.57 Billion 29.88% 0.86x $2.76 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.78 Billion 1.33% 4.40x $596.77 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $364.47 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.26 Billion 16.30% 0.27x $4.46 Billion
Livzon Pharmaceutical Group Inc (000513) $1.83 Billion 2.84% 0.59x $2.54 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.19 Billion
Yunnan Baiyao Group Co Ltd (000538) $32.60 Million 12.25% 0.82x $12.77 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $717.62 Million
Tus Pharmaceutical Group Co Ltd (000590) $702.49 Million 2.58% 0.66x $321.34 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $7.25 Billion 17.08% 0.09x $3.09 Billion

About Apeloa Pharmaceutical Co Ltd

SHE:000739 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.76 Billion
CN¥18.87 Billion CNY
Market Cap Rank
#5277 Global
#1009 in China
Share Price
CN¥16.29
Change (1 day)
-0.37%
52-Week Range
CN¥13.85 - CN¥19.36
All Time High
CN¥39.53
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more